CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Spark’s Take on GB:GSK Stock According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform. GlaxoSmithKline’s stock is supported by strong financial performance and strategic initiatives ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.62; value investors should ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK also boasts an average earnings surprise of 8.6%. With a solid Zacks Rank and top-tier Value and VGM Style Scores, GSK should be on investors' short list. Don’t Miss Out on These Stocks ...

Read GSK PLC Sponsored ADR (NYSE:GSK) ... The institutional investor owned 305,395 shares of the pharmaceutical company’s stock after buying an additional 13,239 shares ...